The Real World Study of Apatinib for Gastric Cancer Treatment in Henan Province

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03478943

Enrollment

1000

Registered

2018-03-27

Start date

2016-01-30

Completion date

2020-12-01

Last updated

2020-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cancer

Brief summary

The investigators conduct the real world study to explore the efficacy and safety of Apatinib in gastric cancer .

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

1. Male or female patients . 2. Confirmed by Pathology or histology of Gastric cancer. 3. Patients should be voluntary to the trial and provide with signed informed consent. 4. The researchers believe patients can benefit from the study.

Exclusion criteria

1. Patients with a known history of allergic reactions and/or hypersensitivity attributed to apatinib or its accessories. 2. Pregnant or lactating women. 3. Patients with Apatinib contraindications. 4. Patients of doctors considered unsuitable for the trial.

Design outcomes

Primary

Measure	Time frame
Progress free survival	1 year
Disease-free surviva	1 year

Secondary

Measure	Time frame
overall survival	3 year
Objective Response Rate	1 year
Disease Control Rate	1 year

Countries

China

Outcome results